3 Things Comeback Kid Exelixis Needs to Do to Succeed in 2017

Published: Nov 18, 2016

Few stocks have performed as well as Exelixis has in 2016. The biotech's share price has nearly tripled this year. Will Exelixis be able to carry this tremendous momentum in to 2017? Mike Morrissey, Exelixis' CEO, spoke at the Stifel Healthcare Conference this week and laid out his view of the biotech's opportunities and challenges. Here are three things Morrissey thinks Exelixis must do to survive and thrive.

Back to news